Predictive markers for the efficacy of anti-PD-1/PD-L1 antibodies in lung cancer

Journal of Thoracic Oncology

Volumn 11, Issue 7, 2016, Pages 976-988

  Shukuya, Takehito ^a   Carbone, David P ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Biomarker; Immunotherapy; Lung cancer; PD 1; PD L1

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; ATEZOLIZUMAB; AVELUMAB; BIOLOGICAL MARKER; CYTOTOXIC AGENT; DURVALUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; GAMMA INTERFERON; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 1 ANTIBODY; PROGRAMMED DEATH 1 RECEPTOR; PROGRAMMED DEATH 1 RECEPTOR ANTIBODY; PROTEIN ANTIBODY; UNCLASSIFIED DRUG; MONOCLONAL ANTIBODY;

CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; DRUG EFFICACY; GENE FUSION; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; NON SMALL CELL LUNG CANCER; ONCOGENE K RAS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SMOKING; TREATMENT RESPONSE; CARCINOMA, NON-SMALL-CELL LUNG; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; LUNG NEOPLASMS; MUTATION; PROGNOSIS;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD274; BIOMARKERS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; INTERFERON-GAMMA; LUNG NEOPLASMS; MUTATION; PROGNOSIS; PROGRAMMED CELL DEATH 1 RECEPTOR; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84978219443     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1016/j.jtho.2016.02.015     Document Type: Review

References (46)

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87-108.
2. Peters S, Adjei AA, Gridelli C, et al. Metastatic nonsmall- cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(suppl 7):vii56-vii64.
3. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines) version 2. 2016. http://www.nccn.org/professionals/physician-gls/f-guidelines.asp. Accessed December 1, 2015.
4. Masters GA, Temin S, Azzoli CG, et al. Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2015;33:3488-3515.
5. Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192:1027-1034.
6. Keir ME, Liang SC, Guleria I, et al. Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med. 2006;203:883-895.
7. Nishimura H, Okazaki T, Tanaka Y, et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science. 2001;291:319-322.
8. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373:123-135.
9. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373:1627-1639.
10. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372:2018-2028.
11. Clinical Trials.gov. https://clinicaltrials.gov/. Accessed December 29, 2015.
12. Horn L, Spigel DR, Gettinger SN, et al. Clinical activity, safety and predictive biomarkers of the engineered antibody MPDL3280A (anti-PDL1) in non-small cell lung cancer (NSCLC): update from a phase Ia study [abstract]. J Clin Oncol. 2015;33(suppl):8029.
13. Vansteenkiste J, Fehrenbacher L, Spira AI, et al. Atezolizumab monotherapy vs docetaxel in 2L/3L non-small cell lung cancer: Primary analyses for efficacy, safety, and predictive biomarkers from a randomized phase II study (POPLAR). Paper presented at: 2015 European Cancer Congress. September 25-29, 2015; Vienna, Austria.
14. Gulley JL, Rajan A, Spigel DR, et al. Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with metastatic or recurrent non-small-cell lung cancer progressing after platinum-based chemotherapy: A phase Ib trial. Paper presented at: 2015 European Cancer Congress. September 25-29, 2015; Vienna, Austria.
15. Higgs BW, Robbins PB, Blake-Haskins JA, et al. High tumoral IFNg mRNA, PD-L1 protein, and combined IFNg mRNA/PD-L1 protein expression associates with response to durvalumab (anti-PD-L1) monotherapy in NSCLC patients. Paper presented at: 2015 European Cancer Congress. September 25-29, 2015; Vienna, Austria.
16. Besse B, Johnson M, Jänne PA, et al. Phase II single-arm trial (BIRCH) of atezolizumab as first-line or subsequent therapy for locally advanced or metastatic PD-L1- selected non-small cell cancer. Paper presented at: 2015 European Cancer Congress. September 25-29, 2015; Vienna, Austria.
17. Spigel DR, Chaft JE, Gettinger SN, et al. Clinical activity and safety from a phase II study (FIR) of MPDL3280A (anti-PDL1) in PD-L1-selected patients with non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol. 2015;33(suppl):8028.
18. Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer. (KEYNOTE-010): a randomised controlled trial [e-pub ahead of print]. Lancet. doi: 10.1016/S0140-6736(15) 01281-7, accessed December 19, 2015.
19. Dong H, Zhu G, Tamada K, et al. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med. 1999;5:1365-1369.
20. Sznol M, Chen L. Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin Cancer Res. 2013;19:1021-1034.
21. Sheffield BS, Geller G, Pleasance E, et al. Predictive biomarker testing for programmed cell death 1 inhibition in non-small cell lung cancer. Presented at: 16th World Conference on Lung Cancer. September 6-9, 2015; Denver, CO.
22. McLaughlin J, Han G, Schalper KA, et al. Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer. JAMA Oncol. 2016;2:46-54.
23. Kowanetz M, Koeppen H, Boe M, et al. Spatiotemporal effects on programmed death ligand 1 (PD-L1) expression and immunophenotype of non-small cell lung cancer (NSCLC). Presented at: 16th World Conference on Lung Cancer. September 6-9, 2015; Denver, CO.
24. Mitchell P, Murone C, Asadi K, et al. PDL-1 Expression in NSCLC: analysis of a large early stage cohort; and concordance of expression in primary, nodes and metastasis. Presented at: 16th World Conference on Lung Cancer. September 6-9, 2015; Denver, CO.
25. Gainor JF, Sequist LV, Shaw AT, et al. Clinical correlation and frequency of programmed death ligand-1 (PD-L1) expression in EGFR-mutant and ALK-rearranged nonsmall cell lung cancer (NSCLC) [abstract]. J Clin Oncol. 2015;33(suppl):8012.
26. Chaft JE, Chao B, Akerley WL, et al. Evaluation of PD-L1 expression in metachronous tumor samples and FDG-PET as a predictive biomarker in ph2 study (FIR) of atezolizumab (MPDL3280A). Presented at: 16th World Conference on Lung Cancer. ORAL02.06. September 6-9, 2015, Denver, CO.
27. Wang A, Wang HY, Liu Y, et al. The prognostic value of PD-L1 expression for non-small cell lung cancer patients: a meta-analysis. Eur J Surg Oncol. 2015;41:450-456.
28. Cooper WA, Tran T, Vilain RE, et al. PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma. Lung Cancer. 2015;89:181-188.
29. Adam J, Boros A, Lacas B, et al. Prognostic value of PDL1 expression in stage III non-small cell lung cancer (NSCLC) treated by chemo-radiotherapy (CRT). Presented at: 16th European Cancer Congress. Presented on September 6-9, 2015; Denver, CO.
30. Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515: 563-567.
31. Antonia SJ, Bendell JC, Taylor MH, et al. Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032 [abstract]. J Clin Oncol. 2015;33(suppl):7503.
32. Ott PA, Elez E, Hiret S, et al. Pembrolizumab for ED SCLC: Efficacy and relationship with PD-L1 expression. Presented at 16th World Conference on Lung Cancer. September 6-9, 2015; Denver, CO.
33. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev. Cancer. 2012;12: 252-264.
34. Ribas A, Robert C, Hodi FS, et al. Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferoninflammatory immune gene signature [abstract]. J Clin Oncol. 2015;33(suppl):3001.
35. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443-2454.
36. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455-2465.
37. Kelderman S, Schumacher TN, Kvistborg P. Mismatch repair-deficient cancers are targets for anti-PD-1 therapy. Cancer Cell. 2015;28:11-13.
38. Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science. 2015;348:69-74.
39. Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348:124-128.
40. Poulogiannis G, Frayling IM, Arends MJ. DNA mismatch repair deficiency in sporadic colorectal cancer and Lynch syndrome. Histopathology. 2010;56:167-179.
41. Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372:2509-2520.
42. Dogan S, Shen R, Ang DC, et al. Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smokingrelated KRAS-mutant cancers. Clin Cancer Res. 2012;18:6169-6177.
43. Govindan R, Ding L, Griffith M, et al. Genomic landscape of non-small cell lung cancer in smokers and neversmokers. Cell. 2012;150:1121-1134.
44. Gettinger SN, Horn L, Gandhi L, et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol. 2015;33:2004-2012.
45. Bauer TM, McCleod M, Chandler JC, et al. An ongoing phase IIIb/IV safety trial of nivolumab (NIVO) in patients (pts) with advanced or metastatic non-small-cell lung cancer (NSCLC) who progressed after receiving 1 or more prior systemic regimens [abstract]. J Clin Oncol. 2015;33(suppl):3013.
46. Yearley J, Gibson C, Yu N, et al. PD-L2 expression in human tumors: relevance to anti-PD-1 therapy in cancer. Paper presented at: 2015 European Cancer Congress. September 25-29, 2015; Vienna, Austria.